Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A Multicenter Phase II Study of AMG 337 in Patients with MET -Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET -Amplified Solid Tumors.

Autor: Van Cutsem E; Department of Digestive Oncology, University Hospitals Gasthuisberg, Leuven, and KU Leuven, Leuven, Belgium. eric.vancutsem@uzleuven.be., Karaszewska B; Department of Oncology, Przychodnia Lekarska NZOZ KOMED, Konin, Poland., Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Shankaran V; Division of Medical Oncology, University of Washington, Seattle, Washington., Siena S; Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda and Dipartimento di Oncologia and Emato-Oncologia, Università degli Studi di Milano, Milan, Italy., Go NF; Clinical Biomarkers and Diagnostics, Amgen Inc., Thousand Oaks, California., Yang H; Global Biostatistical Sciences, Amgen Inc., Thousand Oaks, California., Schupp M; Global Development, Amgen (Europe) GmbH, Zug, Switzerland., Cunningham D; Department of Medicine, Royal Marsden Hospital, London, United Kingdom.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Apr 15; Vol. 25 (8), pp. 2414-2423. Date of Electronic Publication: 2018 Oct 26.